ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Pharmaceuticals

Celltrion spends $450m to ramp up contract drug production

South Korean pharma maker seeks to tap booming overseas demand

Celltrion's headquarters in Incheon, South Korea.   © Reuters

SEOUL -- Major South Korean drugmaker Celltrion will invest 500 billion won ($448 million) to build a factory and an R&D center at its complex in Incheon, adding 60,000 liters to its total annual capacity to meet rising demand for contract manufacturing.

The expansion comes as drug development grows more challenging in general, prompting peers in the U.S. and Europe to increasingly focus on development and outsource production. Celltrion, whose own products include a rheumatoid arthritis treatment, has been tapping this trend and taking in contracting work, increasing manufacturing capacity.

Celltrion, which has two plants at a biohub in Incheon, will complete a third on a nearby 4,700-sq.-meter plot in 2023. The 10,000-sq.-meter R&D site is slated to open in 2022. The investment will create roughly 3,000 jobs, the company says.

The move forms part of Celltrion's plans to scale up production capacity to 600,000 liters by 2030. The Incheon-based company is planning a fourth production site as well.

The company plans small-batch production that accommodates a broader variety of products.

The hub within the Incheon Free Economic Zone is also home to facilities of Samsung Biologics, a contract manufacturer that has broken ground on a 1.74 trillion won fourth plant. Aiming to develop pharmaceuticals into a high-value-added industry similar to semiconductors, the government seeks to foster an environment supporting Celltrion and Samsung Biologics in the economic zone near the international airport, encouraging universities and research institutes to set up shop there.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more